Literature DB >> 20421823

Time trends of surgical outcome in patients with non-small cell lung cancer.

Takeshi Hanagiri1, Tetsuro Baba, Tetsuya So, Manabu Yasuda, Masakazu Sugaya, Kenji Ono, Tomoko So, Hidetaka Uramoto, Mitsuhiro Takenoyama, Kosei Yasumoto.   

Abstract

PURPOSE: A surgical resection is a potentially curative treatment for non-small cell lung cancer (NSCLC). This study investigated the time trends of the surgical outcome in patients with NSCLC.
METHODS: This study clinicopathologically evaluated 1487 patients who had undergone a resection for NSCLC between 1979 and 2008 during the five periods of 1979-1988, 1989-1993, 1994-1998, 1999-2003, and 2004-2008.
RESULTS: The number of patients who underwent a resection during the five respective periods increased: 167, 261, 248, 382, and 429. The percentage of pathologic stage IA lung cancers was 16.2, 21.5, 23.0, 38.5, and 52.0% in each period, respectively, and it has risen rapidly in recent years. The percentage of adenocarcinoma has also progressively increased during each period: 49.1, 52.1, 54.7, 62.8, and 69.7%, respectively. The diameter of the tumors resected during each period was 36, 37, 38, 33, and 26 mm, respectively, showing that the tumor tended to be diagnosed at an increasingly smaller size. The postoperative 5-year survival rates during the five periods improved markedly: 34.1, 44.0, 44.9, 65.4, and 76.5%, respectively. Patients with pathologic stage IA lung cancer also exhibited increasingly higher 5-year survival rates during the five periods: 70.0, 71.2, 80.4, 89.2, and 88.7%, respectively.
CONCLUSION: The prognosis of NSCLC patients has remarkably improved in recent years. The increase in the number of patients with adenocarcinoma in the early stage is thought to have strongly contributed to the favorable results. Thus, early diagnosis remains a key factor for improving the survival of lung cancer patients after surgical treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20421823     DOI: 10.1097/JTO.0b013e3181d5e47f

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  15 in total

1.  A magnetic nanoparticle-based time-resolved fluoroimmunoassay for determination of the cytokeratin 19 fragment in human serum.

Authors:  Guanfeng Lin; Tiancai Liu; Jingyuan Hou; Zhiqi Ren; Jianwei Zhou; Qianni Liang; Zhenhua Chen; Wenqi Dong; Yingsong Wu
Journal:  J Fluoresc       Date:  2015-02-10       Impact factor: 2.217

2.  Simvastatin downregulates expression of TGF-βRII and inhibits proliferation of A549 cells via ERK.

Authors:  Li Shang; Shu-Shan Jia; Hai-Ming Jiang; Hua Wang; Wen-Hua Xu; Chang-Jun Lv
Journal:  Tumour Biol       Date:  2015-01-29

3.  Clinical Characteristics of Resected T3 Non-small Cell Lung Cancer Characterized by Parietal Pleural Invasion or Chest Wall Invasion.

Authors:  Takeshi Hanagiri; Shinji Shinohara; Masaru Takenaka; Hidehiko Shimokawa; Yoshika Nagata; Makoto Nakagawa; Hidetaka Uramoto; Tomoko So; Fumihiro Tanaka
Journal:  Indian J Surg       Date:  2012-07-28       Impact factor: 0.656

4.  β, β-Dimethylacrylshikonin induces mitochondria-dependent apoptosis of human lung adenocarcinoma cells in vitro via p38 pathway activation.

Authors:  Hai-bing Wang; Xiao-qiong Ma
Journal:  Acta Pharmacol Sin       Date:  2014-12-01       Impact factor: 6.150

5.  The tumour shape of lung adenocarcinoma is related to the postoperative prognosis.

Authors:  Tetsuro Baba; Hidetaka Uramoto; Masaru Takenaka; Souichi Oka; Yoshiki Shigematsu; Hidehiko Shimokawa; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-04-18

6.  Clinical significance of human leukocyte antigen loss and melanoma-associated antigen 4 expression in smokers of non-small cell lung cancer patients.

Authors:  Tetsuro Baba; Hironobu Shiota; Koji Kuroda; Yoshiki Shigematsu; Yoshinobu Ichiki; Hidetaka Uramoto; Takeshi Hanagiri; Fumihiro Tanaka
Journal:  Int J Clin Oncol       Date:  2012-11-03       Impact factor: 3.402

7.  Feasibility of adjuvant chemotherapy with S-1 consisting of a 4-week administration and a two-week rest period in patients with completely resected non-small cell lung cancer.

Authors:  Shunsuke Okumura; Takaaki Sasaki; Kazuhiro Satoh; Masahiro Kitada; Atsushi Nagase; Eiji Yatsuyanagi; Yoshinobu Ohsaki
Journal:  Mol Clin Oncol       Date:  2012-08-06

8.  Small interference RNA targeting tissue factor inhibits human lung adenocarcinoma growth in vitro and in vivo.

Authors:  Chengcheng Xu; Qi Gui; Wenshu Chen; Leiming Wu; Wei Sun; Ni Zhang; Qinzi Xu; Jianing Wang; Xiangning Fu
Journal:  J Exp Clin Cancer Res       Date:  2011-05-28

9.  Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage III-N2 non-small cell lung cancer.

Authors:  Takeshi Hanagiri; Masaru Takenaka; Soich Oka; Yoshiki Shigematsu; Yoshika Nagata; Hidehiko Shimokawa; Hidetaka Uramoto; Fumihiro Tanaka
Journal:  J Cardiothorac Surg       Date:  2011-10-25       Impact factor: 1.637

10.  Thyroid transcription factor 1 represses the expression of Ki-67 and induces apoptosis in non-small cell lung cancer.

Authors:  Yun-Fen Zu; Xi-Cai Wang; Yan Chen; Ji-Ying Wang; Xin Liu; Xin Li; Cheng-Wen Li; Yu-Cheng Xie; Yan Luo; Xie-Qin Shang; Jing Guo
Journal:  Oncol Rep       Date:  2012-08-31       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.